Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
HMP.TO 0.03SPGP 1ZUQ.TO 0.55NVDA 0.32GL 1.66MRK -1.71IEMG 0.5GEV 33.87
Novelion (NVLN.TO)

Novelion (NVLN.TO)

0.00
-0.00 (0.00%)
52 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
WEAK BUY

Novelion(NVLN.TO)

Aug 26, 2004
Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down.
Photo of Danny TomkaDanny Tomka
Owned
Unlock Rating
$21.36

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY ON WEAKNESS

Novelion(NVLN.TO)

Aug 23, 2004
At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players.
Photo of Martin Hubbes, CFAMartin Hubbes, CFA
Owned
Unlock Rating
$21.84

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

Aug 17, 2004
The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$21.34

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

Aug 03, 2004
The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$22.20

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jul 30, 2004
The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks.
Photo of Matt BaillieMatt Baillie
No
Unlock Rating
$23.97

Stock price when the opinion was issued

biotechnologypharmaceutical
BUY

Novelion(NVLN.TO)

Jul 22, 2004
Has dropped after the acquisition. Real cheap now.
Photo of Danny TomkaDanny Tomka
Owned
Unlock Rating
$23.15

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jul 14, 2004
Stock just broke below its 200 day moving average. That's a negative sign.
Photo of Ron MeiselsRon MeiselsUnlock Rating
$26.15

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jul 07, 2004
Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$25.09

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Jun 30, 2004
Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$26.60

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

Jun 17, 2004
Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$25.24

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

Jun 14, 2004
Market didn't like news. Wait.
Photo of Ian NakamotoIan NakamotoUnlock Rating
$24.00

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

May 28, 2004
Good company. Well-run. Can't see a lot of upside in terms of news flow.
Photo of Mark Jackson, CFAMark Jackson, CFA
No
Unlock Rating
$31.51

Stock price when the opinion was issued

biotechnologypharmaceutical
HOLD

Novelion(NVLN.TO)

May 11, 2004
Very pleased with its performance. Has been very successful with its main product Visodine. Probably will be range bound for a while. Doesn't have a strong pipeline. Has a lot of cash flow so will be able to make acquisitions.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$35.46

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Apr 20, 2004
Has had a big run and expects it to pause here for a little while. Have a lot of cash. Fully valued.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$39.13

Stock price when the opinion was issued

biotechnologypharmaceutical
DON'T BUY

Novelion(NVLN.TO)

Apr 13, 2004
Getting more and more approvals from HMOs and insurance companies. Probably at a peak right now. Could retreat 10/15%.
Photo of David BaskinDavid BaskinUnlock Rating
$37.20

Stock price when the opinion was issued

biotechnologypharmaceutical
Showing 31 to 45 of 190 entries
The ultimate 360° Tracker Your financial life in one place, automatically

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EPD -0.03$37.25
ET 0.31$19.07
MAIR 0$
RKLB -12.39$102.39
SESG-O 0$

Today's Top Picks

HMP.TO 0.03$9.75
SPGP 1$120.39
ZUQ.TO 0.55$107.47
NVDA 0.32$205.19
GL 1.66$166.76

Popular Articles

Latest Sell Signals

PRGO 0.09$10.99
CBRS 0$
HAWK 0$
AVEX 0$
SWMR 0$

Most Recent Experts

Jim Cramer - Mad Money

Jim Cramer - Mad Money

CNBC

Richard Orrell

Richard Orrell

RN Croft Financial Group

Stockchase Insights

Stockchase Insights

5i Research

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Stan Wong

Stan Wong

Private Wealth Management, ScotiaMcleod

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica